Literature DB >> 20698041

Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Vani J A Konda1, Mark K Ferguson.   

Abstract

High-grade dysplasia (HGD) and intramucosal carcinoma (IMC) in the setting of Barrett's esophagus have traditionally been treated with esophagectomy. However, with the advent of endoscopic mucosal resection and endoscopic ablative therapies, endoscopic therapy at centers with expertise is now an established treatment of Barrett's-esophagus-related neoplasia, including HGD and IMC. Esophagectomy is today reserved for more selected cases with submucosal invasion, evidence for lymph node metastasis, or unsuccessful endoscopic therapy.

Entities:  

Mesh：

Year:  2010        PMID： 20698041      PMCID： PMC2921090          DOI： 10.3748/wjg.v16.i30.3786

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  67 in total

1.  Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.

Authors:  M Kerkhof; H van Dekken; E W Steyerberg; G A Meijer; A H Mulder; A de Bruïne; A Driessen; F J ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Histopathology       Date:  2007-06       Impact factor: 5.087

2.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Authors:  Kenneth K Wang; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

3.  Metaplastic columnar mucosa in the cervical esophagus after esophagectomy.

Authors:  Stefan Oberg; Jan Johansson; Jörgen Wenner; Bruno Walther
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

4.  Acid-related diseases following retrosternal stomach interposition.

Authors:  A Maier; F Tomaselli; O Sankin; U Anegg; B Fell; H Renner; H Pinter; G B Friehs; F M Smolle-Jüttner
Journal:  Hepatogastroenterology       Date:  2001 May-Jun

5.  Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world.

Authors:  J R Siewert; H J Stein; M Feith; B L Bruecher; H Bartels; U Fink
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

6.  Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.

Authors:  A H Ormsby; R E Petras; W H Henricks; T W Rice; L A Rybicki; J E Richter; J R Goldblum
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

7.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

8.  Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia.

Authors:  Christian G Peyre; Steven R DeMeester; Christian Rizzetto; Neeraj Bansal; Andrew L Tang; Shahin Ayazi; Jessica M Leers; John C Lipham; Jeffrey A Hagen; Tom R DeMeester
Journal:  Ann Surg       Date:  2007-10       Impact factor: 12.969

9.  Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?

Authors:  Vani J A Konda; Andrew S Ross; Mark K Ferguson; John A Hart; Shang Lin; Keith Naylor; Amy Noffsinger; Mitchell C Posner; Charles Dye; Barbara Cislo; Lynne Stearns; Irving Waxman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12-21       Impact factor: 11.382

10.  Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

Authors:  Bergein F Overholt; Kenneth K Wang; J Steven Burdick; Charles J Lightdale; Michael Kimmey; Hector R Nava; Michael V Sivak; Norman Nishioka; Hugh Barr; Norman Marcon; Marcos Pedrosa; Mary P Bronner; Michael Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2007-07-23       Impact factor: 9.427
View more
  8 in total

1.  Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Vani Ja Konda; Irving Waxman
Journal:  J Gastrointest Oncol       Date:  2011-03

Review 2.  Minimally invasive esophagectomy for dysplastic Barrett's esophagus.

Authors:  Sheraz R Markar; George Hanna
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 3.  Interventional Therapy of Esophageal Cancer.

Authors:  Aiwu Mao
Journal:  Gastrointest Tumors       Date:  2016-08-27

4.  Gastroesophageal reflux disease: From heartburn to cancer.

Authors:  Marco G Patti; Irving Waxman
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

5.  Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.

Authors:  Vani Ja Konda; Kunal Dalal
Journal:  Ther Clin Risk Manag       Date:  2011-11-22       Impact factor: 2.423

Review 6.  Endoscopic resection of gastric and esophageal cancer.

Authors:  Bryan Balmadrid; Joo Ha Hwang
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-27

Review 7.  Endoscopic methods in the treatment of early-stage esophageal cancer.

Authors:  Wiesław Janusz Kruszewski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-03-24       Impact factor: 1.195

8.  Detection of Second Primary Malignancies of the Esophagus and Hypophraynx in Oral Squamous Cell Carcinoma Patients.

Authors:  Toshihiro Matsui; Takuya Okada; Kenro Kawada; Masahumi Okuda; Taichi Ogo; Yutaka Nakajima; Yuichiro Kume; Tairo Ryotokuji; Akihiro Hoshino; Yutaka Tokairin; Yasuyuki Michi; Hiroyuki Harada; Yasuaki Nakajima; Tatsuyuki Kawano
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.